The diversity of national policies on assisted reproductive technologies (ART) 1 are reflected in the diversity of regulatory schemes in relation to human embryo research, including research to derive stem cells. 2 Broadly, human embryo research national regulation can be classified into three categories of strict, licensing or guideline schemes. The German Embryo Protection Act (Embryonenschutzgestz) reflects German attitudes to research and a highly protective view of human embryos.3 In 2002, the German Parliament allowed embryonic stem cell research but only on imported lines whilst maintaining its strict prohibition on cloning. 4 Other countries maintain bans on embryo research, such as Austria, Ireland and the Philippines. The United Kingdom was the first jurisdiction to introduce a licensing scheme.s The Human Fertilisation and Embryology Authority6 licenses IVF clinics, sets standards for reproductive in the state of Victoria. This Act also placed strict limits on research on human embryos. In 2002, the federal Commonwealth Parliament passed the Research involving Human Embryos Act, which establishes a strict licensing scheme. This article considers this scheme.
Background to licensing regulation in Australia
Australia has had a long record of regulation of assisted reproductive technology, including the world's first legislation, in 1984 in the state of Victoria 12 • Two other Australian States (South Australia 1 3 and Western Australia 1 4) adopted licensing systems for their ART programmes. The legislation in all three States addressed prohibited practices and embryo research 1 
The Infertility Treatment
Act 1995 (Vic) did not prohibit research but has a very "restrictive tilt" 1 6. Any embryo in Victoria used for the purposes of re-implantation 1 7 or 'approved research' 18 has to retain the capacity of that embryo to be re-implanted into a woman. 1 9 This effectively barred the extraction of stem cells from an embryo. This "restrictive tilt" applied in Western Australia and South Australia also 20 • In South Australia,. the approved research was not to be 'detrimental' to the embryo, 21 and, in Western Australia research had to 12 The Infertility (Medical Procedures) Act, see Chalmers D., Professional Self-Regulation and Guidelines in Assisted Reproduction (2002) The Act allows the use of "excess ART (IVF) embryos" to carry out approved research. Criminal offences apply when excess ART embryos are used without a valid licence. The legislation and guidelines include broadly similar provisions dealing with embryo research and establishing a generally "restrictive tilt,"43 including: -Only surplus, "excess" ART embryos may be used; -The consent of the parties creating the embryos is required at 2 stages -The purposes of the research must be explained and mostly the research purposes are limited and require careful justification -The· research purposes must be approved by an Human Research Ethics Committee -The research is generally required to be reported and the research results published -National committees to license or approve the research and, in the case of licensing the power to impose conditions in the licence. 3)(c) ). The HREC must be satisfied that: -the embryos are excess to the needs of the couple in the ART program, -that all the consents have been obtained and -that approval has been given for the activity and project by the HREC.
If the HREC approves, the application can be referred to the National Licensing Committee for consideration.
Excess embryos for licensed research: A key feature of the Act is that only "excess ART embryos" rriay be used. The Act provides that the couple in an ART program must declare their embryos to be surplus to their needs, and consent to the embryos being classified 44 see http:/ /WWW?.health.gov.aujnhmrcjembryojindex. htm as excess under the terms of the Act. These embryos may be then used for research, in strictly limited circumstances. An embryo can only be "excess" if each responsible person (S 8) has authorised in writing the use of the embryo for a purpose other than the ART treatment of the woman concerned (59 (2)(a)). or has determined in writing that the embryo is excess to their needs (sg (2)(b)). Consent is required at 2 stages. Section 24 (1) provides that, before an excess ART embryo is used as authorised by the licence each responsible person (i.e. all those involved in provided the egg or sperm for the creation of the embryo and any spouses). As such, there must first be written authorisation or determination from the woman (and her spouse) that an embryo is an excess ART embryo (sg (2)). Secondly, there must also be consent from each of those people45 that the embryo may be used for an approved research purpose. In effect, the legislation prescribes two separate consents. Consent forms in ART clinics had to be redrafted to reflect these two stages. In addition, the Licensing Committee drafted a guidance note on the consent requirements of the Act and the NHMRC guidelines46.
Consent

Licensing Committee considerations:
Provided the Licensing Committee is satisfied that the relevant consents and HREC approval have been.obtained, the Licensing Committee may consider the application for a licence. The Act requires that the Licensing Committee has regard to the following matters in deciding whether to issue the licence (s21(4)):
45 Potentially, consent may be required from four people (if the egg and sperm are provided by donors) for the particular use of the embryo (s24 (1)(a)). 
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(a) restricting the number of excess ART embryos to that likely to be necessary to achieve the goals of the activity or project proposed in the application; tb) the likelihood of significant advance in knowledge or improvement in technologies for treat~ ment as a result of the use of excess ART embryos proposed in the application, which could not reasonably be achieved by other means; 47 (c) any relevant guidelines, or relevant parts of guidelines, issued by the NHMRC under the 1992 and prescribed by the regulations for the purposes of this paragraph; (d) the HREC assessment of the application mentioned in paragraph (3)(c); (e) such additional matters (if any) as are prescribed by the regulations.
National Health and Medical Research Council Act
In practice, the Licensing Committee's deliberations have concentrated with regard to paragraphs (a) and (b), namely, the issues of restricting the number of excess ART embryos and the likelihood of significant advancement in knowledge or improvement in technologies. Every licence issued so far has included a condition imposed by the Licensing Committee (S 24) about the numbers of embryos that may be used in the research. In addition, the Licensing Committee has developed additional guidance on how it treats the interpretation of the issue of "likelihood of significant advance". 4 8 By comparison, the UK Human Fertilisation and Embryology Authority originally approved research purposes which related principally to understanding of the causes of infertility, miscarriages, genital diseases, contraception and chromosome abnormalities. These purposes were expanded to include research for the purposes of understanding the development of embryos, increasing knowledge of serious disease and the treatment of those diseases.49 47 The Purpose of research criterion is important. In Japan: basic research only is allowed with a ban on reproductive use ofES cells. In the UK: infertility; miscarriages; congenital diseases, contraception; gene/ chromosome abnormalities were the original purposes to which were added development of embryos; knowl- The Act permits destructive research to be carried out on excess embryos. The Act originally distinguished between research that damages or destroys the embryo and non-destructive research (SS 21(3)(b); 24(1)(c); and 24(3). There was a requirement that only "excess" embryos in storage at a particular date. could be used for research that damages or destroys the embryo but this restriction was repealed and not continued5°
Licence grants: The NHMRC Licensing Committee has issued 12licencesS 1 since its inception. In summary, the following table of the LICENSED USE OF EXCESS ART EMBRYOS shows the use of excess ART embryos, as set at 30 September 2007.
See Tabel on page 183
At the time of writing the Licensing Committee is also considering three applications for SCNT licences.
This Table above sets out both the number of embryos that were authorised for use under the Licence and the embryos that have actually been used. Concerns had been expressed during the Parliamentary Debates that the numbers in storage and available for research were around the 70,ooo figure. However, the actual numbers of embryos approved and used for research are substantially below the estimate of numbers of embryos available for research purposes.
Prohibition Of Human Cloning Act (CTH) 2002: The
Licensing Committee is also responsible for administering the Prohibition Of Human Cloning Act. The LC monitors the restrictions created in the Act in the long menu of prohibited practices. These prohibitions are overseen by statutory inspectors and each carrying heavy criminal penalties. These offences are creating an embryo other than by fertilization (S l3) or other than for a pregnancy (S 14); mixing the genetic material of more than 2 people (S15); developing an embryo outside the body of a woman for more than 14 days (S 16); using precursor cells from an embryo to create an embryo (S 17); creating heri- ARTICLES from a broad spectrum of the community including scientists, churches, community groups and IVF representatives. In broad terms, the Legislation Review5 2 concluded that the Licensing Committee was conducting the licensing procedure we'll and overall, the legislation was reflecting effectively the balance view of the parliament to allow research but with restrictions and monitoring.
Two recommendations were of particular importance to the Licensing Committee. First, the Legislation Review recommended that, in some circumstances, it may be permissible to conduct research on live embryos. Embryos undergoing pre-implantation genetic diagnosis could not fulfill the consent procedures required under the Act. If they were considered unsuitable for transfer, they could not be licensed for approved research purposes and had to be discarded. It was argued that som'e of these embryos could be suitable for the development of specific disease stem cell lines for research. No licence has been issued for live, rather than frozen excess embryos.
Secondly, the Review recommended the introduction of licences for somatic cell nuclear transfer. This was a controversial recommendation but one which was consistent with the UK Human Fertilisation and Embryology Authority power to grant licences for such embryos.
As noted above, the legislation originally included a requirement that any excess embryos had to have been in existence on the date of operation of the legislation. This, in effect, required that only frozen embryos could be used. The removal of this specific provision was another enabling amendment allowing the introduction of both SCNT and the possibility of the use of live embryos. These provisions came into force in 2007 Interestingly, this procedure would not require the approval of Licensing Committee, which has been often referred to colloquially in Australia as the "Stem-cell Licensing Committee". In fact, the legislation makes no provision for licensing stem cells.
